Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality

By
Hwa Yeon Ko
Ju-Young Shin
Kyungyeon Jung
Sungho Bea
Bin Hong
Yunha Noh
Jae Hyun Bae
Soo Heon Kwak
Young Min Cho
Ga-young Lim
Jiin Ahn
Seungho Ryu
Ju Hwan Kim
Yoosoo Chang
June 22, 2026
0 min

Jama Network Open

Objective:

To estimate the association between the timing of antidiabetic medication (ADM) initiation and the risk of major adverse cardiovascular events (MACE) and all-cause mortality among individuals with newly diagnosed type 2 diabetes (T2D).

Approach:

Key Findings:

Intensive glycemic control in early diabetes is associated with reduced MACE and mortality.
The legacy effect from early glycemic control persists even after later deterioration.
Evidence on the specific timing of ADM initiation and its impact on cardiovascular outcomes is limited.

Interpretation:

The study clarifies the relationship between the timing of ADM initiation and cardiovascular outcomes in T2D.

Limitations:

Potential selection biases due to observational study design.
Censoring may introduce bias if driven by baseline and postbaseline prognostic factors.
Lack of cause of death data limits the ability to define cardiovascular death.

Conclusion:

The study provides insights into the timing of ADM initiation and its potential impact on cardiovascular events and mortality in T2D patients.

Sources:

Kangbuk Samsung Health Study

Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality

Objective:

Approach:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Sources:

Original Source(s)

Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality

Related Content

Pulse pressure and cardiometabolic disease progression: associations with incident multimorbidity and mortality in UK biobank

Mass Spec Roundup: Ubiquitin, Pollutants, and Pain

Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial